Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Core Insights - Coherus Oncology announced significant six-year overall survival follow-up results from the Phase 3 JUPITER-02 trial, highlighting the survival advantage of LOQTORZI in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma [1][2][7] Group 1: Clinical Trial Results - The Phase 3 JUPITER-02 trial demonstrated that patients receiving LOQTORZI plus chemotherapy achieved a median overall survival of 64.8 months, compared to 33.7 months for those receiving chemotherapy alone, indicating a 31-month improvement and a 38% reduction in the risk of death [2][4][7] - The long-term follow-up results reinforce the potential of LOQTORZI to transform outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma [2][4][6] Group 2: Clinical Implications - The findings suggest a meaningful clinical benefit for patients with RM-NPC, an aggressive cancer with typically limited long-term survival under standard chemotherapy [4][6] - Oncologists may consider incorporating LOQTORZI into first-line treatment regimens to enhance survival outcomes for patients facing challenging prognoses [6][7] Group 3: Company Strategy and Pipeline - Coherus Oncology is focused on advancing its pipeline, which includes LOQTORZI as a next-generation PD-1 inhibitor, aiming to deliver first- and best-in-class therapies [7][35] - The company is strategically positioned to grow sales of LOQTORZI in nasopharyngeal carcinoma and explore new indications through collaborations and proprietary combinations [35][36]